COMMON STOCK PURCHASE WARRANTNymox Pharmaceutical Corp • March 22nd, 2022 • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the fifth anniversary of the Effective Date (as defined in the Purchase Agreement) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 22nd, 2022 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 18, 2022, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 6th, 2021 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances
This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 28, 2021, by and between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
EXHIBIT 2.0 NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY OTHER APPLICABLE UNITED STATES OR CANADIAN SECURITIES LAWS IN RELIANCE UPON...Nymox Pharmaceutical Corp • April 1st, 2002 • In vitro & in vivo diagnostic substances
COMMON STOCK PURCHASE WARRANT NYMOX PHARMACEUTICAL CORPORATIONCommon Stock Purchase Warrant • March 22nd, 2022 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, pursuant to a Placement Agent Agreement by and between A.G.P./Alliance Global Partners and Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”) dated as of March 18, 2022, [____] or its assigns (“Holder”), as registered owner of this Warrant, is entitled at any time on or after the date set forth above as the Initial Exercise Date (the “Initial Exercise Date”), and at or before 5:00 p.m., Eastern time on the fifth anniversary of the Effective Date (as defined in the Purchase Agreement) (the “Termination Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [ ] shares (the “Shares”) of common stock of the Company, no par value per share (the “Common Stock”), subject to adjustment as provided in Section 3 hereof. If the Termination Date is a day on which banking institutions are au
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 14th, 2020 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 12, 2020, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
NYMOX PHARMACEUTICAL CORPORATION and _______________________________, as Trustee INDENTURE Dated as of ___________, 20__ Providing for the Issuance of Debt Securities CROSS-REFERENCE TABLE*Nymox Pharmaceutical Corp • April 24th, 2020 • In vitro & in vivo diagnostic substances • New York
THIS INDENTURE, between Nymox Pharmaceutical Corporation, a Bahamian corporation (hereinafter called the “Company”) having its principal office at Bay & Deveaux Streets, Nassau, The Bahamas, and, [ ], a [ ] as trustee (hereinafter called the “Trustee”), is made and entered into as of this [ ] day of [ ], 20[ ].
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT made as of the 8th day of January, 2000 by and between Nymox Pharmaceutical Corporation, a Canadian corporation (the "Company"), and Judith Fitzpatrick (the "Executive"). W I T N E S S E T H : WHEREAS...Employment Agreement • February 29th, 2000 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New Jersey
Private Placement of Common Stock Purchase WarrantsNymox Pharmaceutical Corp • March 22nd, 2022 • In vitro & in vivo diagnostic substances • New York
This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of shares (the “Shares”) of the Company’s Common Stock, no par value per share (the “Common Stock”), and the common stock purchase warrants to purchase shares of Common Stock (together with the Common Stock, the “Securities”). The Securities actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The terms of the Placement shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”), and nothing herein constitutes that the Placement Agent would have the powe
NYMOX PHARMACEUTICAL CORPORATION and _______________________________, as Trustee INDENTURE Dated as of ___________, 20__ Providing for the Issuance of Debt Securities CROSS-REFERENCE TABLE*Nymox Pharmaceutical Corp • December 9th, 2021 • In vitro & in vivo diagnostic substances • New York
THIS INDENTURE, between Nymox Pharmaceutical Corporation, a Bahamian corporation (hereinafter called the “Company”) having its principal office at Bay & Deveaux Streets, Nassau, The Bahamas, and, [ ], a [ ] as trustee (hereinafter called the “Trustee”), is made and entered into as of this [ ] day of [ ], 20[ ].
NYMOX PHARMACEUTICAL CORPORATION COMMON STOCK SALES AGREEMENTSales Agreement • July 20th, 2020 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follows:
AMENDMENTResearch and License Agreement • July 30th, 2002 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances
COMMON STOCK PRIVATE PURCHASE AGREEMENTCommon Stock Private Purchase Agreement • March 31st, 2016 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • Quebec
This COMMON STOCK PRIVATE PURCHASE AGREEMENT (this “Agreement’) is dated as of November 1, 2013 by and between Nymox Pharmaceutical Corporation, a Canadian corporation (the “Company”), and Lorros-Greyse Investments, Ltd. (the “Purchaser”).
1 EXHIBIT 10.10 RESEARCH AND LICENSE AGREEMENT THIS AGREEMENT is between RHODE ISLAND HOSPITAL CORPORATION, a not-for-profit Rhode Island corporation having offices at 593 Eddy Street, Providence, RI 02903 ("RIH") and NYMOX CORPORATION, a corporation...Research and License Agreement • May 15th, 2000 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • Rhode Island
ARTICLE I DEFINITIONSCommon Stock Purchase Agreement • February 29th, 2000 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
EMPLOYMENT CONTRACTEmployment Contract • March 31st, 2016 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances
E-26 2Registration Rights Agreement • February 29th, 2000 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
ARTICLE I DEFINITIONSCommon Stock Private Purchase Agreement • March 12th, 2003 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • Quebec
E-42Nymox Pharmaceutical Corp • February 29th, 2000 • In vitro & in vivo diagnostic substances
Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, The BahamasNymox Pharmaceutical Corp • December 9th, 2021 • In vitro & in vivo diagnostic substances
Reference is hereby made to that certain sales agreement (the “Agreement”), dated as of July 17, 2020, by and between Nymox Pharmaceutical Corporation (the “Company”) and A.G.P./Alliance Global Partners (“A.G.P.”).
LICENSE AND COLLABORATION AGREEMENT between Nymox Pharmaceutical Corp. and Recordati Ireland Ltd.Supply Agreement • June 3rd, 2011 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
This License and Collaboration Agreement (hereinafter referred to as the “Agreement”) is made and entered into as of the 16th of December 2010 (the “Effective Date”) between Nymox Pharmaceutical Corp., a corporation organized and existing under the laws of Canada, with its principal business office located at 9900 Cavendish Blvd., Suite 306, St. Laurent, Quebec, Canada, H4M 2V2 (hereinafter referred to as “Nymox”), and Recordati Ireland Ltd., a limited liability company organized and existing under the laws of Ireland, with a principal business office located at Raheens East, Ringaskiddy, Co Cork, Ireland (hereinafter referred to as “Recordati”). Each of Nymox and Recordati may be referred to in this Agreement as a “Party” and together as the “Parties”.
EXHIBIT 3.4 (EDGAR EXHIBIT 10.4) SOLE NON-EXCLUSIVE LICENSE AND SUPPLY AGREEMENT FOR THE NYMOX AD7C/TM/ DIAGNOSTIC TEST FOR ALZHEIMER'S DISEASENymox Pharmaceutical Corp • December 9th, 1996 • In vitro & in vivo diagnostic substances • Maryland
NYMOX PHARMACEUTICAL CORPORATION $12,000,000 COMMON SHARES EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • February 9th, 2016 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
Nymox Pharmaceutical Corporation, an international business company organized and existing under the laws of the Commonwealth of The Bahamas (the “Company”), confirms its agreement (this “Agreement”) with Chardan Capital Markets, LLC (“Chardan”), as follows:
ContractNymox Pharmaceutical Corp • March 31st, 2015 • In vitro & in vivo diagnostic substances • Pennsylvania
THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT BE OFFERED FOR SALE OR SOLD UNLESS A REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS SHALL BE EFFECTIVE WITH RESPECT THERETO, OR AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN CONNECTION WITH SUCH OFFER OR SALE.
ARTICLE IEscrow Agreement • February 29th, 2000 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
